Pharma

Your Article Summary

See Latest Articles

Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Repligen, 08/07/09

Repligen Corporation reported results for the first quarter fiscal year 2010, ended June 2009. Total revenue for the quarter was $5,061,000 compared to total revenue of $13,660,000 for the first quarter of fiscal year 2009. The prior year results were favorably impacted by a one–time payment of $6,330,000 by Bristol–Myers Squibb Company for royalties on the U.S. sales of Orencia prior to the April 2008 patent licensing agreement. Total first quarter fiscal year 2010 revenue was comprised of Protein A product revenue of $2,473,000 and royalty and other revenue of $2,588,000, consisting primarily of royalty payments from Bristol–Myers Squibb on the U.S. sales of Orencia and grant revenue from the Muscular Dystrophy Association.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09

Report: Acquisition Activity Down
HealthDataManagement, 12/08/09

Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
Genzyme, 12/07/09

 See all of Financial Reports